In a pair of final guidances published Friday, the FDA outlined acceptable reasons for requesting an extension for responding to a Complete Response Letter (CRL) and provided answers to frequently asked questions about the Orange Book, the agency’s reference text for generic drug substitutions.
Source: Drug Industry Daily